$1.10
10.00% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US74039M1018
Symbol
POAI

Predictive Oncology Inc Stock News

Neutral
GlobeNewsWire
about 22 hours ago
Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing
Neutral
GlobeNewsWire
6 days ago
PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March ...
Neutral
GlobeNewsWire
about 2 months ago
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended Dec...
Neutral
GlobeNewsWire
about 2 months ago
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Neutral
GlobeNewsWire
2 months ago
Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth
Neutral
GlobeNewsWire
3 months ago
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.
Neutral
GlobeNewsWire
3 months ago
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
Neutral
Business Wire
3 months ago
SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today